Consun Pharmaceutical Group Limited (C1P.F)

0.5850 +0.0050 (+0.86%) As of 08:05AM CEST. Market open.

Consun Pharmaceutical Group Limited

71, Dongpeng Avenue
Eastern section Guangzhou Economic and Technological Development Z
Guangzhou
China
86 20 8226 4529
https://www.chinaconsun.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 3,127

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Meng An	CEO & Executive Chairman	2.16M	N/A	1972
Prof. Quan Zhu	Chief Scientist & Executive Director	484.57k	N/A	1940
Mr. Hanxing Xu	Assistant GM, Financial Manager & Executive Director	97.28k	N/A	1994
Mr. Peicheng Fang	CFO & VP	N/A	N/A	1979
Lei Zhou	Assistant President	N/A	N/A	N/A
Mr. Haien Gao	Board Secretary	N/A	N/A	1969
Mr. Chi Ming Yau CPA	Company Secretary	N/A	N/A	1968
Mr. Guorong Guo	Chairman & GM of Guangxi Yulin Pharmaceutical Group Co. Ltd	N/A	N/A	N/A
Ms. Lianhui Chen	Chairman & GM of Consun Pharmaceutical(Inner Mongolia) Co. Ltd	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. The company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; and hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules. It also provides gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Corporate Governance

Consun Pharmaceutical Group Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.